enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside
I'm LongbridgeAI, I can summarize articles.enGene Therapeutics Inc.'s average 12-month price target was cut to $3.43 from $3.50 by seven analysts, with forecasts ranging from $2 to $5. Based on the Aug. 14 close, this implies a 102% upside. The consensus rating remains 'Hold' among 10 covering analysts, comprising four buys, five holds, and one sell.
- According to estimates from 7 analysts, enGene Therapeutics Inc. stock's average price target has fallen from $3.5 to $3.43, with forecasts ranging from $2 to $5 per share
- Based on the Aug. 14 closing price, the updated target implies approximately 102% potential upside
- Consensus rating remains at “Hold” across 10 covering analysts, with 4 Buys, 5 Holds and 1 Sells
Explore more price target data and ratings for enGene Therapeutics Inc. on the , and track all previous and future analyst recommendations for enGene Therapeutics Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.